It’s hard to keep up with the pace of development in the mass tort space. However, we at The Expert Institute live to make your life easier. Therefore, we’ve compiled some of the best mass tort news from some of the leading legal voices online today. The posts below will help you stay apprised of the very latest in the world of mass torts.
Essure Risks May Outweigh Benefits Of Permanent Birth Control Device
Top Class Actions works to connect consumers with reliable news and information regarding the current landscape of class action litigation. As well as giving forward-looking perspectives on potential litigation. A hot topic in the world of mass torts, Bayer’s permanent birth control product Essure continues to draw the attention of plaintiff law firms and regulators alike. With a recent change to the labeling for the birth control product carrying stronger warnings of the potential risks of the device; Essure will likely remain a focus for the plaintiff mass tort bar for the remainder of the year. Read their fantastic summary on Essure’s risks, as well as the regulatory response to patient complaints, on the Top Class Actions site.
Diabetes Medicine Invokana Gets New Warning About Lower Limb Amputation Added To Drug Package Insert In Canada
Drug Injury Watch is the brainchild of Tom Lamb. He is a drug injury attorney who has been representing clients on a nationwide basis for the past 17 years. His blog is packed with in-depth evaluations of the medical literature, regulatory responses, and litigation surrounding consumer pharmaceuticals and medical devices. By keeping his finger on the pulse of medical regulators and pharmaceutical industry news; Tom uncovers developments in drug injury litigation that others may miss. Such as this fantastic insight into a lesser-known risk of Diabetes drug Invokana – lower limb amputation.
Does Carcinogenicity Classification Make Any Sense?
Innovative Science Solutions is a consulting firm of scientists, regulatory specialists, and other consultants. It works closely with global leaders in the pharmaceutical, biotechnology, and medical device industries. The company’s blog reflects the caliber of minds working there; it’s packed with detailed, yet easy to digest, insights into technical topics with a focus on legal applications. Their December 20th article on carcinogenicity classifications is a prime example of the great content they produce. It also has some immediate relevance to major product liability actions centered on allegedly carcinogenic ingredients like talc.
Baby Powder Lawsuit: Did You Know Its Possible Link to Ovarian Cancer?
Drug Lawsuit Source takes a holistic approach to sharing information on medical devices and drugs that have become the subject of class action lawsuits. While much has been said on the alleged cancer risk of Johnson & Johnson’s iconic baby powder, Drug Lawsuit Source has published one of the most detailed explanations of the growing litigation. Starting with an outline of the product’s origins in 1892 as a novel combination of fragrance and Italian talcum; the post offers a substantive history of the product’s development and the medical research that has suggested a potential link to cancer since the early 80’s.
Feds Recover $4.7B from Drug Companies, Other Industries
Drugwatch is often the first result when googling any medical device or pharmaceutical litigation, and for good reason. The site is constantly updated with blog posts, detailed white papers with primary research, and podcasts on the latest in drug-related litigation and FDA recalls. Where Drugwatch really shines, however, is in its current litigation and lawsuit coverage. It sheds light on trends and events that may otherwise have flown under the radar. There’s no better example of this insightful coverage than their recent January 4th article on fraud recoveries made by the federal government under the False Claims Act. Learn how over half of those recoveries came from the drug and medical device industry; and why the Justice Department has recovered over $19.3 billion in healthcare fraud claims since 2009. This is all in the full article on the Drugwatch site.
